BioVaxys Technology Corp. (BVAXF)

BioVaxys Technology Income Statement

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Selling, General & Admin	3.53	2.82	2.12	2.34	4.12	0.42
Research & Development	0.03	0	0.13	0.96	0.73	0.24
Operating Expenses	3.92	3.12	2.4	3.8	5.98	1.01
Operating Income	-3.92	-3.12	-2.4	-3.8	-5.98	-1.01
Interest & Investment Income	-	-	-	-	0	0
Currency Exchange Gain (Loss)	-0.06	-0	-0.03	-0.02	-0.02	-0
Other Non Operating Income (Expenses)	-0.21	-0.17	-4.03	-0.26	-0.46	-0.09
EBT Excluding Unusual Items	-4.19	-3.3	-6.46	-4.08	-6.46	-1.1
Asset Writedown	-1.29	-1.29	-1.45	-7.4	-	-
Other Unusual Items	-0.07	0.63	0.21	-0.25	-	-
Pretax Income	-5.54	-3.95	-7.69	-11.73	-6.46	-1.1
Earnings From Continuing Operations	-5.54	-3.95	-7.69	-11.73	-6.46	-1.1
Earnings From Discontinued Operations	-	-	-	-	-	-0.07
Net Income	-5.54	-3.95	-7.69	-11.73	-6.46	-1.17
Net Income to Common	-5.54	-3.95	-7.69	-11.73	-6.46	-1.17
Shares Outstanding (Basic)	225	196	134	98	83	28
Shares Outstanding (Diluted)	225	196	134	98	83	28
Shares Change (YoY)	58.48%	45.90%	36.63%	18.39%	193.97%	171.65%
EPS (Basic)	-0.02	-0.02	-0.06	-0.12	-0.08	-0.04
EPS (Diluted)	-0.02	-0.02	-0.06	-0.12	-0.08	-0.04
EBIT	-3.92	-3.12	-2.4	-3.8	-5.98	-1.01
Advertising Expenses	-	0.42	-	0.17	1.72	0.08

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.